PP61. Warfarin Therapy after Endovascular Aneurysm Repair (EVAR) of the Abdominal Aorta: Effect on Endoleak Development  by Bobadilla, Joseph & Tefera, Girma
JOURNAL OF VASCULAR SURGERY
May Supplement 200932S Poster PresentationsTerumo, Scotland) between September 2005 and September 2008 were
prospectively recorded. Patients were divided in Group A (proximal neck
angle  60° or iliac arteries angle  90°) and Group B (all others). Main
endpoints were technical success (primary and assisted) clinical outcome and
survival. Results in the two groups were compared by KaplanMayer life table
analysis with logrank test (Mantel-Cox).
Results: One-hundred patients, with a mean age of 73.87.0 years,
were treated. Mean aneurysm diameter was 5.6710.4 cm. A severe
angulation of the proximal aortic neck or/and iliac arteries was present in
37 cases (Group A). Patients without a severe angle were 63 (Group B)
The mean follow-up was 20.510.7 months. Overall primary technical
success was achieved in 100% of the patients. At 24 months follow-up,
overall survival, primary and assisted clinical success were 87.9%, 80.8%
and 93.7% respectively. Survival, primary and assisted clinical success
were 97.2%, 87.9% and 91.1% in Group A and 82.4%, 76.8% and 95.2%
in Group B respectively. No statistically significant differences were
found between the two groups.
Conclusion: Aneurysms with severe neck or iliac arteries angulation
can be treated by a ring-stent endograft with results similar of those of AAA
with more favourable anatomy. Longer follow-up is awaited to determine
the role of this kind of endograft in AAA treatment.
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Endovascular Aneurysm Repair (EVAR) in Nonagenarians is Safe and
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Harry L Bush, Jr., John K Karwowski. New York Presbyterian Hospital,
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Objectives: Advanced age is a significant risk factor that has steered
patients away from open aneurysm repair and towards expectant man-
agement. The reduced morbidity and mortality of stent grafting, how-
ever, permits aneurysm repair in patients previously considered too high
a risk for open surgery. We report our experience with EVAR in nona-
genarians.
Methods: A retrospective chart review identified all patients &gt;90 years
old undergoing EVAR over a 10-year period at our institution. Collected data
included preoperative co-morbidities, peri-operative complications, endoleaks,
reinterventions, and long term survival. Anesthetic choice and endograft selec-
tion were based on patient co-morbidities, anatomy, and surgeon preference.
Means were compared using the Student’s t-test.
Results: 23 patients underwent endovascular aneurysm repair (EVAR).
The mean age was 91.5 years (range 90-94), with 15 (65%) males and 8 (35%)
females. Mean abdominal aortic aneurysm diameter was 6.31.1 cm. Eight
patients (35%) were symptomatic (pain or tenderness). There were no ruptures.
13 patients (57%) had general anesthesia while 10 (43%) had local or regional
anesthesia. 12 Cook Zenith grafts, 2 Medtronic Talent grafts, 9 Medtronic
Aneurx grafts, and 1 Guidant Ancure graft were used. Mean post-operative
length of stay was 3.12.4 days (2.51.8 days for asymptomatic vs 4.13.2
days for symptomatic, p0.14). There was one peri-operative mortality (4.3%)
following EVAR for a symptomatic aneurysm. This occurred after discharge at
post-operative day 26 secondary to a myocardial infarction. There were 2 groin
seromas (8.7%) and 4 systemic complications (17.4%) including 2 myocardial
infarctions, 1 episode of atrial fibrillation, and one gastrointestinal bleed. In
follow-up, one patient required re-intervention for endoleak (4.3%).Therewere
no aneurysm related deaths beyond the 30-day post-operative period. Mean
survival beyond 30 days was 800459 days following EVAR. EVAR patients
still alive have a mean survival of 795506 days.
Conclusions: This is the largest reported EVAR series in nonagenari-
ans. Despite their advanced age, these patients benefit from EVAR with low
morbidity, low mortality, and survival exceeding 2.2 years. With or without
symptoms, patients over the age of 90 should be considered for EVAR.
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Objectives: The presence of an endoleak after endovascular aneurysm
repair (EVAR)may leave patients vulnerable to sac expansion and potentially
sac rupture. We investigated whether anticoagulation with warfarin was anindependent risk factor for endoleak formation after EVAR for abdominal
aortic aneurysm (AAA).
Methods: From January 2000 to January 2007 all endovascular AAA
procedures were captured in a clinical database. Follow-up at 1 month, 6
months, 12 months, and annually thereafter was routine. Patient demo-
graphics, co-morbidities, morbidity and mortality, EVAR device, and anti-
coagulation therapy were recorded. The presence of endoleak was classified
and reported according to published guidelines. Kaplan-Meyer survival
analysis was used to determine freedom from an endoleak. Rank sum and
t-test analyses were used to assess patient characteristics as a determinant of
risk for endoleak. P0.05 achieved statistical significance.
Result: OneHundred and twenty seven consecutive endovascular repairs
were examined. The mean age of patients at EVAR was 73.8 and mean
aneurysm size at was 5.9cm.Median time to follow up was 26 months. During
this time period there were 38 documented endoleaks [Type I (n8), Type II
(n28), Type III (n1), Type IV (n1)] which required which 12 secondary
procedures. Patients on warfarin therapy (n24) were compared to patients on
anti-platelet therapy (n103). There were no significant differences in age
(p0.36), initial aneurysm size (p0.36), initial post-operative aneurysm sac
volume (p0.59), or duration of follow-up (p0.23). There was, however, a
significant decrease in freedom from endoleak in the group of patients on
warfarin (p0.0075). Additionally, postoperative volumetric analysis showed a
net increase in aneurysm sac volumeof 14.4% in thewarfarin group compared to
a 4.34% decrease in the anti-platelet patients.
Conclusions: Warfarin appears to increase the incidence of endoleak
after EVAR. This, in turn, is associated with continued aneurysm sac
expansion.
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Objectives: We examined the current practice of open repair of abdomi-
nal aortic aneurysms (AAA) at a university hospital. We hypothesized that
endovascular aortic repair (EVAR) has become the standard approach to AAA
repair and that exclusion from EVAR was most often on anatomic grounds.
Methods: All patients undergoing open AAA repair or EVAR between
April 2004 and October 2008 were prospectively entered into a database, and
the rationale for open repair was identified retrospectively.We excluded patients
undergoing thoracoabdominal aneurysm repair requiring cardiopulmonary bypass.
Results: Over 54 months, 882 patients underwent AAA repair. EVAR
was performed in 570 (64.6%); 312 (35.4%) patients had open repair. Among
those treatedwith open repair, 215 (69%)weremen and97 (31%)werewomen,
the average agewas 72.4 years, and the averagemaximal aneurysmdiameterwas
6.3 cm. The overall 30-day mortality for open repair was 4.1%, while 30-day
mortality for elective open repair was 2.8%. Of those patients undergoing open
repair, 56% (176/312) were juxtarenal (20%), suprarenal (14%), or type IV
thoracoabdominal aortic aneurysms (22%). Meanwhile, 10% of patients (31/
312) had inadequate access vessels for EVAR and 15% (46/312) had aorto-bi-
iliac aneurysms, while 24% (74/312) of patients had infrarenal AAA’s with
hostile proximal necks. Finally, 5% of patients (17/312) underwent open
conversion of EVAR. 36 of 312 (11%) patients met multiple EVAR exclusion
criteria. Only three (0.9%) patients who underwent open repair were clearly
eligible for EVAR on anatomic grounds.
Conclusions: Over one-third of patients with AAA were ineligible for
EVAR and required open repair. Given that only three patients underwent open
repair preferentially, EVAR appears to be the standard treatment for eligible
patients. Open repair is most commonly performed for juxtarenal or more
proximal AAA or hostile proximal neck anatomy. This study reinforces the need
for novel devices capable of sealing stent grafts in the pararenal and visceral aorta.
Single-center experience in open AAA repair
Selected reasons for open repair Number (%)
Conversion of prior EVAR 17/312 (5.4%)
Distal obstruction (inadequate vascular access) 31/312 (10%)
Aorto-bi-iliac aneurysm 46/312 (15%)
Juxtarenal AAA, Suprarenal AAA, or Type IV TAAA 176/312 (56%)
Hostile neck 74/312 (24%)
Neck  2cm in length 53/312 (17%)
Neck  32 mm in diameter 9/312 (2.9%)
Neck trapezoidal 4/312 (1.3%)
Neck angulated 8/312 (2.6%)
